| January 15, 2015 | ISSUE NUMBER 384 VOL 4 |
|
Special Feature
What’s Ahead? Pharm Exec’s 2015 Industry Forecast
Following a year where a phenomenal cure was met by pricing outrage, the march of new products and promising immunotherapy cancer combos will continue in 2015. As pharma and tech jell, how will the industry live up to its value supposition while pricing and profiting in the developed and developing worlds? ...Read more
learn more about how to leverage Data and Analytics to enhance Copay Program Performance with this White Paper and Case Study.  Read more
From the Editor
Five Years, Five Key Performance Measures: How Has Industry Fared?
Five years ago, Pharm Exec Editor William Looney offered up a prediction: that the future of the biopharmaceutical business depended on how managers fared on five key measures of performance. At the start of a new year that also ranks "high on the five," it's appropriate to assess industry's progress ...Read more
Opinion
Moving Beyond the Blame Game
Pharma and healthcare companies are putting more of their energies into building partnerships that can deliver high-quality care to the greatest number of people, writes Novo Nordisk’s Jesper Høiland
...Read more
Risk
Loss Aversion: Reducing the Risk of New Prescription Drugs
In an increasingly competitive marketplace, with greater understanding of behavioral biases such as loss aversion, how can pharma professionals use loss aversion to propel brands to success? And how can the benefit (or risk) be tipped in favor of changing current behaviors? Dr. Pamela Walker reports
...Read more
Regulatory
FDA Extends Track and Trace Enforcement Deadline
Latest guidance says that FDA does not intend to enforce the requirements for providing or capturing transaction information, transaction history, and transaction statements each time a product changes hands until May 1, 2015 ...Read more
|
|
|
|
 //TB Alliance (New York, NY) announced the appointment of Mario Raviglione, MD, Director of the Global TB Program at the World Health Organization (WHO), and Shalini Sharp, Chief Financial Officer of Ultragenyx Pharmaceutical, to its Board of Directors.//AmnioLife Corporation (Gainesville, DFA) appointed Andrew S. Hoover as Chief Financial Officer.//Alacrita (Cambridge, MA) recruited William (Bill) Slichenmyer, MD, as an Associate Partner.//Ohr Pharmaceutical (New York, NY) announced that Jason Slakter, MD, Chief Medical Officer, has been appointed to the company's Board of Directors.//Heptares Therapeutics (Boston, MA, and London, UK) appointed Atul Pande and Roberto Solari to its Board of Directors.// |
|
|
|
|
|
